Overview

the study to investigate the efficacy of empagiflozin in pediatric heart failure

Eligibility

Inclusion Criteria:

• • Pediatrics (aged 1months-18 years)
  • Confirmed HF diagnosis:

HF will be defined by reduced ventricular systolic function (left ventricular ejection fraction by echocardiography) or impaired ventricular filling (pulmonary capillary wedge pressure \> 18 mmHg measured directly and/or the ratio of early diastolic mitral inflow velocity(E) to early diastolic mitral annular velocity (e')( E/e'\>14 by echocardiography) with clinical features of congestion and/or low cardiac output.

• Class III or IV of ROSS classification or BNP level more than 300 pg/mL

Exclusion Criteria:

• • Pediatric with chronic kidney failure
  • Avoid initiating empagliflozin in patients with concurrent urinary tract infection (UTI).
  • patients with eGFR \<60 mL/minute/1.73 m2 will be excluded.
  • Patients with contraindication to empagliflozin usage which include
    • eGFR \<30 mL/minute/1.73 m2
    • Hypersensitivity (eg, angioedema) to empagliflozin